Expert Point of View: Jeffrey Bradley, MD

Get Permission

Commenting on both radiotherapy studies and the use of proton-beam therapy in general, Jeffrey Bradley, MD, of Washington University in St Louis, agreed with both presenters that a randomized prospective trial is needed to justify the use of proton-beam therapy in prostate cancer.

Washington University is building its own proton-beam center, the first single-room system in the world. Dr. Bradley noted that at this point, prostate cancer is not at the top of the list of diseases treated with proton-beam therapy.

“With limited resources, we will tend to use [proton-beam therapy] where there is a proven benefit—in children and to treat diseases near the base of the skull, brain, and eye. Proton-beam therapy may enable a shorter treatment time and spares normal tissue, but we need a randomized trial to establish its use in prostate cancer,” Dr. Bradley said. ■

Disclosure:Dr. Bradley reported no potential conflicts of interest.

Related Articles

Early Quality of Life Better with Proton-beam Therapy, but Late Effects Similar to Other Treatment Modalities for Prostate Cancer

Differing patterns of patient-reported quality of life for three-dimensional (3D) conformal radiotherapy, intensity-modulated radiation therapy, and proton-beam therapy were reported in a nonrandomized comparison of three modern cohorts of patients with prostate cancer. The study was presented at...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.